These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1661859)

  • 1. Evaluation of the sites of opioid influence on anterior pituitary hormone secretion using a quaternary opiate antagonist.
    Simpkins JW; Swager D; Millard WJ
    Neuroendocrinology; 1991 Oct; 54(4):384-90. PubMed ID: 1661859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of melatonin in vivo upon luteinizing hormone and prolactin releases induced by opiate receptor antagonists in adult male rats.
    Shacoori V; Saïag B; Lemay V; Girre A; Rault B
    J Endocrinol Invest; 1996 Feb; 19(2):76-82. PubMed ID: 8778169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin modifies prolactin release induced by opiate antagonists in male rats.
    Shacoori V; Saiag B; Rault B
    Endocr Res; 1995 Aug; 21(3):545-53. PubMed ID: 7588425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates.
    Simpkins JW; Smulkowski M; Dixon R; Tuttle R
    J Pharmacol Exp Ther; 1988 Jan; 244(1):195-205. PubMed ID: 3335997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the duration of action of nalmefene and naloxone on the hypothalamic-pituitary axis of the rhesus monkey.
    VanVugt DA; Webb MY; Reid RL
    Neuroendocrinology; 1989 Mar; 49(3):275-80. PubMed ID: 2716954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats.
    June HL; Cummings R; Eiler WJ; Foster KL; McKay PF; Seyoum R; Garcia M; McCane S; Grey C; Hawkins SE; Mason D
    Neuropsychopharmacology; 2004 Feb; 29(2):285-99. PubMed ID: 14603266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of opiate antagonists on serotonin turnover and on luteinizing hormone and prolactin secretion in estrogen- or morphine-treated rats.
    Johnson MD; Crowley WR
    Neuroendocrinology; 1984 Apr; 38(4):322-7. PubMed ID: 6328344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of multiple opiate receptors through neuroendocrine responses. II. Antagonism of mu, kappa and sigma agonists by naloxone and WIN 44,441-3.
    Pechnick R; George R; Poland RE
    J Pharmacol Exp Ther; 1985 Jan; 232(1):170-7. PubMed ID: 2981314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo characterization of the opioid antagonist nalmefene in mice.
    Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
    Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of chronic naloxone on pituitary hormone secretion in female rats.
    Gabriel SM; Simpkins JW; Millard WJ
    Brain Res Bull; 1984 Apr; 12(4):359-62. PubMed ID: 6329481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central opioid receptors mediate glucoprivic inhibition of pituitary LH secretion.
    Briski KP
    Am J Physiol; 1997 Apr; 272(4 Pt 1):E517-22. PubMed ID: 9142869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential role of the opioid mu and delta receptors in the activation of prolactin (PRL) and growth hormone (GH) secretion by morphine in the male rat.
    Koenig JI; Mayfield MA; McCann SM; Krulich L
    Life Sci; 1984 May; 34(19):1829-37. PubMed ID: 6330479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.
    Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
    Neuroendocrinology; 1986; 42(1):75-81. PubMed ID: 3001565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys.
    France CP; Gerak LR
    J Pharmacol Exp Ther; 1994 Sep; 270(3):992-9. PubMed ID: 7932212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implication of opiates in the glucocorticoid-mediated inhibition of LH secretion in rats.
    Belhadj H; de Besi L; Bardin CW; Thau RB
    J Endocrinol; 1989 Aug; 122(2):451-6. PubMed ID: 2671240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyridine-sensitive calcium channel activity related to prolactin, growth hormone, and luteinizing hormone release from anterior pituitary cells in culture: interactions with somatostatin, dopamine, and estrogens.
    Drouva SV; Rerat E; Bihoreau C; Laplante E; Rasolonjanahary R; Clauser H; Kordon C
    Endocrinology; 1988 Dec; 123(6):2762-73. PubMed ID: 2461851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
    Walker BM; Koob GF
    Neuropsychopharmacology; 2008 Feb; 33(3):643-52. PubMed ID: 17473837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.